Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desipramine + fluoxetine is a combination of two antidepressant medications used together, primarily studied for the treatment of major depressive disorder. Desipramine is a tricyclic antidepressant (TCA) that acts mainly by inhibiting the reuptake of norepinephrine, thereby increasing its activity in the brain. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels by blocking its reabsorption into neurons. The combination has been investigated for potential synergistic effects, with some studies suggesting it may lead to more rapid and effective symptom improvement compared to monotherapy with either agent alone. However, combining these drugs can increase the risk of side effects and drug interactions due to pharmacokinetic interactions—fluoxetine inhibits CYP2D6, which can raise desipramine plasma levels and increase toxicity risk[1][2][5]. This combination should be used under close medical supervision.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desipramine + fluoxetine.